The painful thing is that these results are materially similar to what was already reported. When you have a bimodal distribution split roughly 50/50, with an endpoint based on median OS, you're already on the raggedy edge. Forty percent of patients could have great results and yet this benefit could be invisible in the median OS.
If a biomarker/responder profile emerges then this drug could be significant. I know, "if" is such a big word for so few letters.
I wonder if algorithms are set to look for some combination of "not" and a variation of "statistical significance" and trigger a sell. I'm only partly serious, but that's about how the market seems to react.
You have to look at the data in-aggregate. It's a small study with a variable patient population. But we see numerical superiority of OCR-002 for reduction of plasma ammonia, in the context of statistically significant reduction in urine ammonia levels (and even in a small study), with a drug with a straightforward mechanism of action. This is more suggestive of an effective drug rather than a failed drug.